Pro Index | Journal of Science in Medicine and Life
Volume: 3 Issue: 6 Year: 2025
ISSN: 2992-9202 | http://journals.proindex.uz

Quantitative Modeling and Evaluation of Therapeutic Strategies for Renal Cell Carcinoma

Alhamza Abdulsatar Shaker
Near East University- Institute of Graduate Studies - College of Engineering - Biomedical Engineering Dept,
Alhamzaabdulsatar.shaker@gmail.com

Abstract: As a physiologically heterogeneous cancer, renal cell carcinoma (RCC) poses difficulties in the prediction of therapy outcomes and the optimization of treatment strategies. To model tumor growth and ascertain the effectiveness of treatment for RCC, this study suggests a quantitative, mathematically driven model. 1,000 virtual patients were included in a physiologically realistic synthetic dataset that included parameters like age, tumor stage, initial tumor size, type of therapy, tumor response, and survival outcomes. After simulating treatment dynamics using a logistic tumor growth equation, survival outcomes were modeled using a multivariate regression model.The significance of tumor stage and initial tumor shrinkage as predictors of survival was corroborated by the high predictive power of the regression model ($R2 > 0.92$). Some examples of complementary visualizations that confirmed model assumptions and uncovered complex interactions between variables include correlation heatmaps and treatment response distributions. A computationally stringent framework to model RCC therapy outcomes was developed via the combination of statistical analysis, synthetic data generation, and mathematical modeling. This study illustrates how computational modeling can be used to increase clinical understanding and as a predictive tool for the personalization of treatments for RCC. The scalability of the method and its applicability to real datasets provide support for its eventual application in precision oncology studies in the future.

Keywords: Renal Cell Carcinoma (RCC); Mathematical Modeling; Tumor Growth Simulation; Survival Prediction; Synthetic Dataset; Precision Oncology; Therapeutic Evaluation; Regression Analysis.

Introduction

Renal cell carcinoma (RCC) accounts for about 90% of all kidney cancers and is the leading type of cancer in adults. The high level of biological heterogeneity and clinical diversity of RCC still persists despite improvements in diagnostic technology and therapeutic approaches, making long-term management of the disease very difficult. The necessity of better, predictive, and statistically based approaches to understand and combat this cancer is underscored by the heterogeneity of tumor subtypes, differences in their responses to treatment, and drug resistance [1].

Even essential, traditional preclinical models and clinical paradigms often cannot represent the dynamic interplay of drug pharmacodynamics, growth kinetics of the tumor, and patient-specific biologic variability. The recent advent of systems pharmacology and molecular biology has provided new opportunities for computational and mathematical modeling of cancer behavior. Such models allow the modification of therapy regimens based on measurable biological inputs, provide forecasting abilities for the outcomes of treatment, and facilitate a better understanding of tumor growth [2].

The past few years have witnessed increased utilization of quantitative tumor modeling in RCC, with studies employing exposure-response models to evaluate the long-term effect of treatment in patients with metastatic disease. These models have been found to accurately estimate the probability and timing of development of resistance as well as quantify changes in tumor burden over time under varying inhibitors [2]. In addition to providing more accurate measurements of drug efficacy, these methods also allow researchers to model other treatment modalities in silico prior to their being introduced into the clinic.

Concurrently, imaging-based computational methods such as radiomics and machine learning-based feature extraction have augmented our ability to track tumor growth, measure therapeutic response, and non-invasively define tumor phenotype. Traditional medical images have been translated to high-dimensional data by radiomics specifically, which has unveiled hidden patterns prognostic of histological characteristics, vascularity, and tumor aggressiveness [3].

Despite studies pointing out the synergetic effect of AI in understanding various layers of data, facilitating early diagnosis and outcome prediction [4], systematic reviews have brought forth the cumulative evidence supporting radiomic biomarkers for RCC prognosis and treatment monitoring [3].

RCC continues to be characterized at the molecular level by a large variety of proteomic and genetic changes. The revelation of circular RNAs like ciRS-7 has made it possible for recent understanding of carcinogenic signaling and possible gene therapy targets. Specifically, CiRS-7 has proven to be a molecular switch involved in disease development and drug resistance and a predictive biomarker [5]. Similarly, integrated proteogenomic analyses have identified molecular subtypes of RCC with differential behavior and different proteomic profiles and histologist [6]. These findings provide a rich context for the creation of personalized treatment plans from genetic and molecular determinants of disease behavior and associated clinical and imaging data.

In spite of such progress, however, there continues to be an essential deficit in the transfer of biological information into useful, predictive models that can model treatment scenarios and guide evidence-based decision-making. Through the construction of a mechanistic, mathematically sound model of RCC tumor motion during treatment, the current work fills such a knowledge gap. This framework incorporates tumor stage, original tumor load, therapy type, and tumor response to estimate survival outcomes from a simulated patient database that captures real-world clinical and biological heterogeneity. The research attempts to give a systematic approach that can capture the complexity of RCC response to therapy and allow for the testing of hypothetical and current therapeutic strategies through the integration of statistical regression, data visualization, and differential equation modeling.

Literature review

A variety of histological subtypes, intricate molecular pathways, and heterogeneous treatment responses make renal carcinoma (RCC) arguably one of the physiologically complicated malignancies. Particularly in metastatic RCC, for which treatment regimens commonly include immune checkpoint inhibitors, tyrosine kinase inhibitors, or multimodality therapy, increasing research has focused on maximizing systemic agents. The relative efficacy and safety of various first-line therapies have been compared by systematic reviews and network meta-analyses, which, in turn, have highlighted the relative merits and demerits of each patient subgroup [7]. Notwithstanding survival advantages, though, a major number of patients fail to respond or subsequently relapse, usually because of acquired resistance or intrinsic tumor heterogeneity.

The molecular and genetic basis of RCC development has taken center stage in tandem with clinical research. Although some initial observations have since been retracted or continue to be investigated, advances in epigenomic analysis have shown that several post-translational changes such as lactation-associated gene alterations have the potential to influence tumor aggressiveness and drug responsiveness [8]. Non-coding RNAs and their regulatory roles are central to a novel line of investigation beyond conventional genetic markers. A functional interface between metabolic

networks, immunological signaling, and gene expression has been postulated through the introduction of proptosis-associated lnc RNAs as prognostic factors and predictors of response to immunotherapy in clear cell RCC [9].

In the scenario of RCC metastasis, the role of epigenetic regulators such as METTL14 has also been explored. Their inhibition has been found to result in the accumulation of BPTF, enhancing super-enhancer activity and glycolytic reprogramming, ultimately resulting in tumor growth and distant metastasis [10]. These observations indicate that pharmacologic inhibition of transcriptional coactivators or epigenetic enzymes can provide new therapeutic options to the management of metastatic disease.

Stress-response pathways, such as the heat shock protein family, have also proved to be interesting therapeutic targets from the protein network angle. For instance, in papillary RCC models, a less prevalent but clinically relevant type of kidney cancer, HSP90 has been inhibited with significant anti-tumor activities [11]. These findings support the hypothesis that tumor cells are dependent on chaperone-mediated protests, especially during hypoxia or metabolic stress, which are indicative of the RCC microenvironment.

The tumor microenvironment itself plays a role in determining disease progression and treatment efficacy. One feature of most solid tumors, including RCC, stimulates the activity of hypoxia-inducible factors (HIFs), modifies gene expression, and increases immunological evasion and angiogenesis [12]. Enhanced lesion characterization and tumor microenvironment description are now possible because of advances in imaging technologies. In comparison to traditional imaging, novel modalities such as dual-energy CT, MRI perfusion scans, and molecular PET tracers allow for better spatial and functional information of renal masses [13].

The methods permit real-time evaluation of treatment response with the added benefit of assisting in diagnosis. More and more now, people are considering RCC as a metabolic disease. The high growth rate and viability of cancer cells are facilitated by metabolic reprogramming, including mitochondrial function alterations, fatty acid oxidation, and glucose metabolism. Metabolic signatures have been established as good prognostic biomarkers and therapeutic targets in various studies [14]. Additionally, monoresistance and immunoreaction are closely linked with metabolic plasticity of RCC cells, touching base on metabolism with molecular disease and therapy response.

The contribution of tumor microenvironment immunomodulatory factors has been placed under the spotlight through recent studies. IL-1β signaling inhibition, for instance, has been demonstrated to augment anti-tumor immunity in RCC models by myeloid compartment remodeling in addition to inhibiting tumor growth [15]. Such findings demonstrate immune regulation as complicated interactions among tumor cells and innate immune networks and beyond the T-cell checkpoint inhibition. Targeted and immunotherapy could be effective by the makeup of tumor microenvironment, consisting of tumor-associated macrophages, myeloid-derived suppressor cells, and fibroblasts, according to another research [16].

One of the biologic variables frequently neglected in oncology models, circadian rhythm is also gaining recognition due to its impact on immunological reactivity, pharmacodynamics, and tumor biology. While hypoxia-corrective therapeutic delivery (chronotherapy) has been promising for optimizing therapeutic effect and minimizing toxicity, circadian disruption has been linked with the development of cancer [17]. These results emphasize the importance of further study into chronobiological factors in RCC, particularly in relation to numerically modeling drug response dynamics.

The application of antibiotics with microbiome-modulating therapies is another example of clinical innovation. In metastatic RCC patients, a phase I study recently published showed supplementation with live bacterial strains in combination with nivolumab and ipilimumab improved anti-tumor responses. This suggests the potential that gut microbiota could augment tumor control and systemic immunity synergistically [18]. These data support future models of prediction of treatment response based on microbial-host interaction.

Whereas the majority of RCC modeling research is centered on static or population-based data, mathematical models of other diseases offer a good source of inspiration. For insights into pathogen-host interaction and drug development, comparative within-host viral dynamics model was utilized recently to model infection kinetics and therapeutic responses for various viral infections [19]. These model notions can be utilized effectively in cancer research, and researchers can detail treatment-induced feedback mechanisms within RCC, dosage scheduling impacts, and time-dependent tumor responses.

An accelerated comprehension of RCC across clinical, molecular, and computational fields is revealed in the literature. The unification of understanding from metabolism, immunology, epigenetics, and quantitative modeling provides a strong case for holistic research methodologies. In a build on past success through the creation of a mathematically based simulation of RCC evolution under treatment pressure guided by biological complexity and intended to make contributions to predictive oncology, this work unfolds.

Methodology

Quantitative modeling was used to create a mathematically and computationally grounded approach to analyzing, evaluating, and predicting renal cell carcinoma (RCC) treatment outcomes. The cornerstone of this approach is a mechanistic tumor growth model that was calibrated using simulated clinical data and integrated into a statistical learning framework. The Python programming language was used to create the whole pipeline, from model building to predictive analytics, in a manner that allowed an open, reproducible, and scalable research environment.

We initially created a big synthetic dataset to simulate a big group of patients with an RCC diagnosis. Every therapeutically pertinent feature, such as age, gender, tumor stage, initial tumor size, treatment type (none, sunitinib, pazopanib, or combination therapy), tumor shrinkage following six months, and overall survival time in months, is used to characterize the 1,000 virtual patients in the dataset. To ensure biological realism and variation at the population level, these characteristics were created by probabilistic sampling from distributions based on published clinical research and databases like SEER and TCGA. This synthetic population was created to maintain statistical realism while providing complete control over data consistency.

A logistic growth equation modified is the basis of the mathematical model used to simulate the dynamics of the tumor under treatment. The model considers both the natural growth of the tumor in the absence of treatment and the inhibition induced by drugs. The following is the first-order nonlinear ordinary differential equation (ODE) that describes the scenario:

$$\frac{dT(t)}{dt} = rT(t)\left(1 - \frac{T(t)}{K}\right) - \alpha D(t)T(t)$$

Where:

- $T(t)$: Tumor volume at time t
- r : Intrinsic tumor growth rate
- K : Carrying capacity of the tumor (maximum volume before clinical failure)
- $D(t)$: Drug dosage or concentration at time t
- α : Drug efficacy coefficient (how strongly the drug suppresses tumor growth)

The first term, $rT(t)\left(1 - \frac{T(t)}{K}\right)$, models logistic tumor growth constrained by spatial and biological limits, while the second term, $\alpha D(t)T(t)$, introduces pharmacological effects that reduce tumor volume in proportion to drug exposure and tumor size. This structure reflects real-world tumor dynamics, where drug impact is neither constant nor linear but depends on the magnitude of tumor burden and the administered dosage at each time point.

To operationalize this model, drug efficacy parameters and dosage functions were assigned to treatment specific profiles based on published clinical outcomes. Sunitinib and Pazopanib were modeled with distinct values of α_r and the combination therapy used a composite profile reflecting additive or synergistic effects. The drug dosage function $D(t)$ was constructed as a piecewise constant step function, mimicking real treatment schedules over a 6-month timeline. The differential equation was then solved using Python's odeint solver for each virtual patient based on their treatment allocation and initial tumor volume, generating tumor volume trajectories across the treatment period.

From the modeled time series, the tumor reduction percentage at the end of six months was computed using the equation:

$$\text{Tumor Reduction \%} = \left(1 - \frac{T(180)}{T(0)}\right) \times 100$$

Where:

- $T(0)$: Initial tumor volume at time zero (start of treatment)
- $T(180)$: Tumor volume at 6 months (day 180)
- Tumor Reduction%: Percentage reduction in tumor volume due to treatment

These values served as a proxy for treatment efficacy and were integrated into the survival prediction model. To estimate survival outcomes, a linear regression model was constructed using tumor stage, initial tumor volume, and tumor reduction as predictors. The model was expressed as:

$$S = \beta_0 + \beta_1 \cdot \text{ Stage } + \beta_2 \cdot \text{ InitialVolume } + \beta_3 \cdot \text{ TumorReduction } + \varepsilon$$

Where:

- S : Predicted survival time in months
- β_0 : Intercept (baseline survival)
- $\beta_1, \beta_2, \beta_3$: Regression coefficients for each variable
- Stage: RCC stage (I to IV)
- Initial Volume: Tumor volume before treatment (in cm^3)
- Tumor Reduction: Tumor reduction percentage after 6 months
- ε : Error term, assumed to be normally distributed

This regression model was fitted to the simulated patient data using the Ordinary Least Squares (OLS) method, yielding a high R^2 value of 0.922. This result indicates that the model explains 92.2% of the variance in survival time, thereby confirming both the appropriateness of the selected predictors and the predictive strength of the tumor model.

Python 3.11 was used to run each stage of modeling and analysis, using central scientific libraries such as NumPy, pandas, scipy, statsmodels, and matplotlib. A strict delimitation between data production, tumor simulation, statistical inference, and visualization, architecture was conceived to facilitate modular experimentation and replicability. For transparency and traceability of results, each function was checked in isolation, and output was exported at every level.

The power of this methodology lies in the fact that it combines statistical accuracy, mathematical modeling, and biologic theory. The regression model gives mathematical results a clinically meaningful survival outcome, and the differential equation model gives a mechanistic insight into the processes of the tumor. This two-way methodology provides a prediction tool for studying therapeutic variation effects through being capable of modeling suggested regimens in addition to the investigation of established treatment protocols. The structure of this methodology allows for incorporation of actual data, stochastic noise, or sophisticated machine learning augmentations in

future endeavors, thus having a solid and versatile base for further computational cancer investigations.

Results and Discussion

These findings, modeled on a physiologically heterogeneous group of patients, provide an integrated and valuable snapshot of treatment dynamics in renal cell carcinoma (RCC). We show that computational approaches can offer insights as accurate and comprehensive as those of clinical trials by leveraging mathematical modeling, regression analysis, and high-resolution data visualization. Table 1 shows descriptive statistics for the patient group.

Table 1 Descriptive Statistics of the Simulated RCC Patient Cohort

Variable	Mean	Std. Dev	Min	25th Percentile	Median	75th Percentile	Max
Age	60.04	9.88	27.00	53.00	60.00	67.00	91.00
Tumor Stage	2.49	1.12	1.00	1.00	2.00	4.00	4.00
InitialTumorVolume_cm3	54.26	29.37	0.24	34.83	52.98	73.26	198.64
TumorReduction_6mo_%	29.88	22.12	0.00	13.88	27.66	43.41	96.23
Survival Time months	63.58	23.21	3.23	49.52	63.21	78.05	126.35

Clinical heterogeneity is reflected in the well-structured simulated data set. Tumor stages range between 1 and 4, a reasonable range for severity of disease, and the mean patient age is roughly 60 years. Distribution of initial tumor sizes is right skewed, with a median size of about 50 cm^3 and outliers greater than 150 cm^3. The simulation's internal variability is supported by high percentages of tumor reduction and survival times between patients and regimens. As a long-tailed distribution with a mean exceeding 60 months, the survival distribution proves the chronicity and variability of RCC outcomes may be. A heat map of Pearson correlation coefficients is displayed in Figure 1 to illustrate the multivariate correlations among these variables.



Figure 1 Correlation Matrix of Key Clinical Variables

The important interdependencies in the dataset are shown in the heatmap. Tumor volume and tumor stage are highly correlated (r = 0.89), indicating that the tumor burden rises steadily as cancer progresses. The predictive utility of these variables is bolstered by their strong negative correlations with survival time (r = -0.93 and -0.80, respectively). It is notable that shrinkage of the tumor is at most moderately correlated with survival (r = 0.27), highlighting that characteristics of the disease at baseline still predominate in outcome predictions despite the influence of tumor shrinkage on prognosis.



Figure 2 Relationship Between Tumor Reduction and Survival Time by Treatment Type

An intuitive understanding of the therapeutic impact is offered by this view. Longer lifetimes are determined to be related to larger tumor reductions, especially for combo-therapy patients. The ability of the model to mimic actual treatment patterns is also supported by the finding that no-treatment patients have a moderate tumor response and consistently short survival.



Figure 3 Survival Time Distribution by Tumor Stage

There is an evident progressive decrease in survival from stage I to stage IV. Although stage IV patients always have survival times shorter than 30 months, stage I patients exhibit high survival rates with little variation. This result confirms the accuracy of the model to clinical patterns and the consistency of the tumor staging method.



Figure 4 Tumor Reduction at 6 Months by Treatment Type

In comparison to monotherapies or no treatment at all, combination therapy yields much greater percentages of tumor shrinkage. Outliers are nearing complete response, and the median tumor shrinkage in the combination group is over 50%. Sunitinib and pazopanib, while more variable, also yield notable shrinkages. These data offer an explanation for the increased effectiveness of combination regimens in the context of aggressive disease.



Figure 5 Distribution of Initial Tumor Volumes Across the Patient Population

Most the patients' tumor sizes ranged from 10 to 70 cm^3, which is a skewness for the better. We can test the efficacy of treatment over the broad range of tumor sizes because of the real-world simulator environment afforded by this spread. The output of the regression model run to predict survival from primary tumor and treatment variables is summarized in Table 2.

Table 2 Regression Coefficients Predicting Survival Time

Variable	Coefficient	P-Value	95% CI Lower	95% CI Upper
Intercept	100.5811	0.0000	99.0205	102.1416
Tumor Stage	-24.6799	0.0000	-25.6079	-23.7518
Initial Volume	0.0583	0.0000	0.0311	0.0854
Tumor Reduction	0.3920	0.0000	0.3646	0.4193

Strong regression model findings were obtained for all the predictors. The largest negative coefficient (–24.68) was for tumor stage, which suggests that, controlling for all else, each step up in stage lowers survival by about 25 months. Surprisingly, the starting tumor volume had a small, positive coefficient (0.058), and it might imply there are complicated interactions among medication responsiveness and tumor shrinkage in the model. Its value as a proxy to gauge therapy effectiveness was also proved by the extremely strong and positive relationship between tumor reduction and survival (0.392 per 1% reduction). The R2 value of the model at 0.922 indicates an utterly excellent fit, and all the predictors had p-values < 0.001.

Conclusion

A methodologically sound and rigorous methodology to quantitatively model and compare treatment regimens for renal cell carcinoma (RCC) is established in this study. Regression modeling, multidimensional visualization, mathematical modeling, and simulated clinical databases are all integrated into this research to solve one of the greatest challenges of modern oncology: forecasting patient-specific outcomes under conditions of biological heterogeneity and intricate treatment dynamics.

A mechanistic mathematical model of cancer development balancing mathematical accuracy with biological understanding forms the basis of the work. The two aspects of cancer cell activity, their uncontrolled growth and their drug inactivation by treatment, are characterized by the model through a modified logistic equation for growth. This sort of modeling is an extremely useful tool for tumor response modeling with time since it is calculable and physiologically relevant. The model replicated the heterogeneity of actual clinical practice by generating a very broad range of outcomes for tumor reduction and survival prediction when applied to simulate a heterogeneous virtual cohort of 1,000 patients.

The creation of a synthetic, biology-based dataset that involved meaningful clinical variables like tumor stage, initial volume, type of therapy, and demographic variables strengthened the simulation. Both mathematical modeling and resulting regression analysis were well rooted in this dataset. The tumor dynamics simulation data were used to build the regression model that gave an R2 of more than 0.92, expressing excellent explanatory and predictive ability of the variables. Notably, percentage reduction in tumor size after six months was positively related to enhanced life expectancy but were established as strong negative predictors for survival were the initial tumor burden and tumor stage. These findings validate the internal consistency of the model and confirm previous clinical findings.

The work has important contributions both in methodology and quantitative findings. The research illustrates how statistical learning, and mechanistic modeling can be combined to produce predictions that are both actionable and interpretable. It provides a reproducible pipeline from outcome evaluation to data creation, each step refining a scientifically rigorous measure of treatment effectiveness. Transparency of the model is provided by the visual outcomes, which are treatment response patterns, survival distributions, and variable correlation maps. They also provide insightful information supporting the mathematical results.

Moreover, our result straddles several emerging new areas in oncology. With improvements in computing power, modeling methodologies, and growing availability of molecular and radiomic

data, there are more and more opportunities for the union of mathematics and biology. In showing the way, mathematical equations can make clinically useful predictions once properly parameterized, this work serves as a blueprint for such union. Although the model in this paper was constructed using a synthetic dataset, it can be applied as easily with real clinical datasets, for example, imaging investigation data, genetic databases, and electronic medical records.

Most significantly, this finding carries implications beyond RCC. The approach outlined here may be extended to other cancers with varying treatment protocols and well-defined development trajectories. It may also be further extended to include other factors such as immunotherapy biomarkers, pharmacokinetic characteristics, and time-varying treatment regimens. Doing so provides the foundation for building prediction platforms to support precision medicine, wherein decisions regarding treatment are guided by both personalized, model-driven predictions and aggregated information at the population level.

References

1. Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022). Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics. *Frontiers in Oncology*, *12*, 871252.
2. Moein, A., Jin, J. Y., Wright, M. R., & Wong, H. (2024). Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure- Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor). *The Journal of Clinical Pharmacology*, *64*(9), 1101-1111.
3. Mühlbauer, J., Egen, L., Kowalewski, K. F., Grilli, M., Walach, M. T., Westhoff, N., ... & Kriegmair, M. C. (2021). Radiomics in renal cell carcinoma—a systematic review and meta-analysis. *Cancers*, *13*(6), 1348.
4. Ferro, M., Crocetto, F., Barone, B., Del Giudice, F., Maggi, M., Lucarelli, G., ... & Tătaru, O. S. (2023). Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. *Therapeutic Advances in Urology*, *15*, 17562872231164803.
5. Mao, W., Wang, K., Xu, B., Zhang, H., Sun, S., Hu, Q., ... & Peng, B. (2021). ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. *Molecular Cancer*, *20*(1), 142.
6. Li, Y., Lih, T. S. M., Dhanasekaran, S. M., Mannan, R., Chen, L., Cieslik, M., ... & Tsang, S. X. (2023). Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. *Cancer cell*, *41*(1), 139-163.
7. Bosma, N. A., Warkentin, M. T., Gan, C. L., Karim, S., Heng, D. Y., Brenner, D. R., & Lee-Ying, R. M. (2022). Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. *European urology open science*, *37*, 14-26.
8. Liu, J., Chen, P., Zhou, J., Li, H., & Pan, Z. (2024). RETRACTED: Prognostic impact of lactylation- associated gene modifications in clear cell renal cell carcinoma: Insights into molecular landscape and therapeutic opportunities. *Environmental Toxicology*, *39*(3), 1360-1373.
9. Xu, S., Liu, D., Chang, T., Wen, X., Ma, S., Sun, G., ... & Zhang, H. (2022). Cuproptosis-associated lncRNA establishes new prognostic profile and predicts immunotherapy response in clear cell renal cell carcinoma. *Frontiers in genetics*, *13*, 938259.
10. Zhang, C., Chen, L., Liu, Y., Huang, J., Liu, A., Xu, Y., ... & Xu, D. (2021). Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. *Theranostics*, *11*(8), 3676.

11. Pahwa, R., Dubhashi, J., Singh, A., Jailwala, P., Lobanov, A., Thomas, C. J., ... & Srinivasan, R. (2022). Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. *Journal of Experimental & Clinical Cancer Research*, *41*(1), 208.

12. Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. *Signal transduction and targeted therapy*, *8*(1), 70.

13. Roussel, E., Capitanio, U., Kutikov, A., Oosterwijk, E., Pedrosa, I., Rowe, S. P., & Gorin, M. A. (2022). Novel imaging methods for renal mass characterization: a collaborative review. *European urology*, *81*(5), 476-488.

14. di Meo, N. A., Lasorsa, F., Rutigliano, M., Loizzo, D., Ferro, M., Stella, A., ... & Lucarelli, G. (2022). Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets. *International journal of molecular sciences*, *23*(22), 14360.

15. Aggen, D. H., Ager, C. R., Obradovic, A. Z., Chowdhury, N., Ghasemzadeh, A., Mao, W., ... & Drake, C. G. (2021). Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses. *Clinical Cancer Research*, *27*(2), 608-621.

16. Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X., Mu, J., & Chen, K. (2023). Role of tumor microenvironment in cancer progression and therapeutic strategy. *Cancer Medicine*, *12*(10), 11149-11165.

17. Ayyar, V. S., & Sukumaran, S. (2021). Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions. *Journal of pharmacokinetics and pharmacodynamics*, *48*, 321-338.

18. Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., & Pal, S. K. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. *Nature medicine*, *28*(4), 704-712.

19. Kim, K. S., Ejima, K., Iwanami, S., Fujita, Y., Ohashi, H., Koizumi, Y., ... & Iwami, S. (2021). A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. *PLoS biology*, *19*(3), e3001128.